|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardiology Research Laboratory, Lawson Health Research Institute, London Health Sciences Centre, Departments of Medicine, Physiology, and Pharmacology, University of Western Ontario, London, Ontario, Canada N6A 4G5
| |
ABSTRACT |
|---|
|
|
|---|
We recently demonstrated that mice
deficient in endothelial nitric oxide (NO) synthase (eNOS) have
congenital septal defects and postnatal heart failure. However, the
mechanisms by which eNOS affects heart development are not clear. We
hypothesized that deficiency in eNOS impairs myocardial angiogenesis.
Myocardial capillary densities were measured morphometrically in
neonatal mouse hearts. In vitro tube formation on Matrigel was
investigated in cardiac endothelial cells. In vivo myocardial
angiogenesis was performed by implanting Matrigel in the left
ventricular myocardium. Myocardial capillary densities and
VEGF mRNA expression were decreased in neonatal
eNOS
/
compared with neonatal wild-type mice
(P < 0.01). Furthermore, in vitro tube formation from
cardiac endothelial cells and in vivo myocardial angiogenesis were
attenuated in eNOS
/
compared with wild-type mice
(P < 0.01). In vitro tube formation was inhibited by
NG-nitro-L-arginine methyl ester in
wild-type mice and restored by a NO donor, diethylenetriamine-NO, in
eNOS
/
mice (P < 0.05). In conclusion,
deficiency in eNOS decreases VEGF expression and impairs myocardial
angiogenesis and capillary development. Decreased myocardial
angiogenesis may contribute to cardiac abnormalities during heart
development in eNOS
/
mice.
heart; endothelial cells; vascular endothelial growth factor; knockout mice; capillary development
| |
INTRODUCTION |
|---|
|
|
|---|
ANGIOGENESIS is the development of new blood vessels from preexisting blood vessels, a complex process involving dissolution of basement membrane underlying endothelial cells, endothelial cell migration, adhesion, proliferation, and organization into tubes, followed by lumen formation (26, 28). Vascularization occurs concomitantly to organ growth, and angiogenesis is an event involved closely in organ development and tissue repair. Organized blood vessel formation is essential for physiological function of organs. Angiogenesis is a multistep process controlled by the balance of pro- and antiangiogenic factors (26, 28).
Nitric oxide (NO) production from endothelial NO synthase (eNOS)
plays an important role in normal fetal development. Mice deficient in
eNOS show fetal growth restriction, reduced survival, and an increased
rate of limb abnormalities (14). Furthermore, eNOS
/
mice have a high incidence of bicuspid aortic
valve (18). We recently demonstrated that a deficiency in
eNOS led to increased cardiomyocyte apoptosis, congenital
septal defects, and postnatal heart failure (9),
suggesting that eNOS is important in fetal heart development. However,
the mechanisms by which eNOS affects fetal heart development are not
clear. Recent studies have demonstrated that NO production is essential
for angiogenesis in hindlimb ischemia (20), wound
healing (17), and coronary collateral growth after myocardial ischemia (19). VEGF is a key mediator
of angiogenesis under physiological and pathological conditions
(10). Inhibition of VEGF leads to impaired organ
development and increased mortality (12). The angiogenic
effect of VEGF is predominantly mediated by eNOS (11). NO
production from eNOS is not only a downstream mediator of VEGF-induced
angiogenesis (20) but also an upstream promoter of VEGF
expression (15). It seems that there is a positive feedback mechanism between NO and VEGF that promotes angiogenesis. However, the role of eNOS in myocardial angiogenesis during heart development is still not fully understood. In the present study, we
hypothesized that a deficiency in eNOS results in decreases in
myocardial VEGF expression and angiogenesis in neonatal hearts. Impaired angiogenesis in the myocardium may contribute to myocardial apoptosis, heart failure, and high mortality in neonatal
eNOS
/
mice (9).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals.
The animals used in this study were handled in accordance with the
guidelines of the Animal Care Committee at the University of Western
Ontario, Ontario, Canada. Breeding pairs of eNOS
/
and
C57BL/6 wild-type mice were purchased from Jackson Laboratory (Bar
Harbor, ME). A breeding program was carried out to produce neonates.
Mice were genotyped by a PCR method using genomic DNA extracted from
the tail.
Analysis of myocardial capillary densities.
Neonatal wide-type C57BL/6 and eNOS
/
mice
at postnatal day 1 were used for stereology analysis
of myocardial capillary vasculature similar to previously described
methods (29) with modifications. Under a stereomicroscope,
the chest was opened from the sternum. An equal volume mixture of 3%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) and cardioplegia
solution (120 mM NaCl and 30 mM KCl) was slowly infused into the left
ventricular chamber using a microsyringe to perfuse the heart. Hearts
were removed, placed in cardioplegia for 1 min, fixed with 3%
glutaraldehyde in 0.1 M phosphate buffer for another 2 h, and then
postfixed in 1% osmium teroxide in phosphate buffer (pH 7.2). The
heart samples were embedded with Epon-araldite plastic mixture. A
dissecting microscope was used to make sure that the heart was embedded
in proper position so that transverse sections were obtained.
One-micrometer sections were cut, starting from the apex of the heart
along the long axis of the left ventricle. Sections that showed double
ventricular chambers were placed on glass slides and stained with
Richardson's solution (mixture of 1% azure II in distilled water and
1% methylene blue in 1% sodium borate). Subepicardial regions of the
left ventricular free wall on the sections were photographed in
sequence by using a digital camera under a microscope (Leitz) at a
magnification of ×400. Twelve to fourteen images were taken for one
heart section. Capillaries were assessed by the SigmaScan Pro program.
Capillaries were defined as those structures possessing a patent lumen
formed by a single endothelial cell and usually containing red blood cells. Photographed fields from each heart included a total of ~150-300 capillary profiles. The combined photographed sample fields from each neonatal mouse heart averaged 0.069 mm2.
The number of capillaries in the sample fields was counted and expressed as capillary density per millimeter squared. Measurement of
capillary densities in adult mouse hearts was performed in the same way
as that in neonatal mice.
Immunohistochemistry.
Hearts isolated from wild-type and eNOS
/
neonatal mice
were fixed in 10% neutral buffer formaldehyde, embedded in paraffin, and cut into 5-µm sections. Identification of endothelial cells was
performed using an antibody against von Willebrand factor (vWF; DAKO).
In brief, tissue sections were incubated in 0.3% hydrogen peroxide for
20 min to block endogenous peroxidase activity. To prevent nonspecific
binding, sections were preincubated for 30 min in PBS containing horse
serum. The sections were then incubated with rabbit anti-human vWF
antibody (1:200). The sections were subsequently incubated with swine
anti-rabbit IgG antibody (1:100, DAKO), followed by incubation with
rabbit proxidase anti-peroxidase complex (1:50, DAKO). Staining for vWF
was visualized with 3-diaminobenzidine substrate, which produces a
yellow-brown color. Sections were counterstained with hematoxylin.
Isolation and purification of cardiac endothelial cells. Cardiac endothelial cells were isolated using a modification of previously described methods (27). Briefly, after the heparinized (5,000 U/kg) mice were euthanized by cervical dislocation, ventricles were aseptically removed and transferred to ice-cold HBSS. The tissue was minced and incubated with HBSS containing 500 U/ml collagenase II (Worthington), 0.6 U/ml dispase II (Boehringer Mannheim), and 0.1% (wt/vol) BSA (Sigma) for 40 min at 37°C. The digested material was filtered through 100-µm nylon mesh and washed twice. Subsequently, the cells were incubated with microbeads (Dynal beads M-450, Dynal) coated with lectin (Griffonia simplicifolia-1, Sigma) in medium 199 (M199) supplemented with 1% FCS at room temperature for 15 min. Microbeads attached to endothelial cells were captured by Dynal magnet and seeded onto gelatin-coated 35 × 10-mm tissue culture dishes in M199 supplemented with 20% FCS, 50 µg/ml endothelial cell growth supplement (ECGS), 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 U/ml of heparin. Cardiac endothelial cells were grown to confluence before they were passed to Matrigel (BD Matrigel Matrix, BD Biosciences)-coated 96-well plates.
In vitro two-dimensional cardiac endothelial cells culture.
Matrigel contains various growth factors including endothelial
growth factors, platelet-derived growth factor, insulin growth factor
1, and transforming growth factor-
. Matrigel stored at
20°C was
thawed at 4°C overnight. A cooled pipette was used to mix the
Matrigel to homogeneity, which was then diluted 1:1 in ice-cold
serum-free DMEM. The 96-well plates were coated with the diluted
Matrigel (50 µl/well), incubated at 37°C for 1 h, and then
washed with serum-free DMEM. Endothelial cells (3 × 104 cells) were seeded onto each well and cultured at
37°C for 4 h in DMEM supplemented with 20% FCS, 25 µg/ml
ECGS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 U/ml
heparin. The NOS inhibitor NG-nitro-L-arginine methyl ester
(L-NAME; 500 µM, Sigma) or the NO donor
diethylenetriamine-NO (DETA-NO; 2 µM, Sigma) was added to the medium
at the time of seeding. Cells were observed with an inverted microscope
and photographed using a digital camera at ×400 magnification at
4 h after seeding. In vitro angiogenesis was assessed by the
formation of capillary-like structures from cardiac endothelial cells
on Matrigel, as previously described (4). To measure the
formation of the capillary-like network, the number of connections
between three or more capillary-like structures was counted and
expressed as the number of capillary connections per field.
Furthermore, the average thickness of the tube or cell overcrowding,
the total length of tubes per field, and the average length (distance)
of tube between connections were quantified by image analysis with an
image analysis system (SigmaPro).
In vivo Matrigel angiogenesis.
In vivo angiogenesis was assessed as the growth of blood vessels from
myocardial tissue into a Matrigel plug implanted in wild-type and
eNOS
/
mice (10-13 wk). Matrigel was stored at
20°C and thawed at 4°C for 2 h before use (24).
The mouse was anesthetized with ketamine (55 mg/kg) plus xylazine (15 mg/kg), intubated, and artificially ventilated with room air. Tidal
volume was set at 0.6 ml with 90 breaths/min and a 40/60
inspiration-to-expiration ratio (SAR-830, CWE). Body temperature was
maintained at 37°C. A left thoracotomy was performed, and the heart
was exposed. Matrigel was injected into the anterior wall of the left
ventricle near the apex at a total volume of 8 µl using a 29-gauge
needle adapted to a Hamilton microsyringe. To prevent leakage of
Matrigel from the hole of puncture, the needle was kept in myocardium
for ~30 s after injection. The chest was closed by sutures in layers.
Three days after injection, the mice were killed, and the hearts were
harvested, fixed in 10% neutral buffered formalin, and embedded in
paraffin. Transversal sections (5 µm) were cut sequentially
from the apex to base of the heart, stained with hematoxylin and eosin,
and examined under a microscope. The vessel area and total Matrigel
area were planimetrically assessed from three different sections.
Results are expressed as the percentage of the vessel area to the total
Matrigel area.
RT-PCR. The mRNA expression of VEGF was determined by RT-PCR similar to the method that we described previously (8). Total RNA was isolated from the left ventricular myocardium with TRIZol reagent (GIBCO-BRL). The RNA was extracted with the use of phenol-chloroform, precipitated by isopropanol, and quantified by spectrophotometry. Subsequently, RNA was reverse transcribed into first-strand cDNA using a Moloney murine leukemia virus reverse transcriptase system. The cDNA was amplified by PCR using a programmable thermal cycler (Progene, Techne; Cambridge, UK). The forward and reverse primers for the mouse VEGF gene (Genbank Accession No. NM009505) were 5'-ACC TCA CCA AAG CCA GCA CA-3' and 5'-GGC ATG GTG GTG ACA TGG TT-3', respectively. To ensure that equal amounts of reverse-transcribed cDNA were added to the PCR mixture, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Genbank Accession No. M17701) was also amplified using the following primers: forward primer, 5'-AAA GGG CAT CCT GGG CTA CA-3'; reverse primer, 5'-CAG TGT TGG GGG CTG AGT TG-3'. The logarithmic ranges of amplification were established for VEGF and GAPDH (35 and 25 cycles, respectively) to ensure that the amplified PCR product reflected the original mRNA level. The PCR product was separated on a 2% agarose gel and visualized under UV light. The predicted lengths of the amplification product for VEGF and GAPDH were 334 and 297 bp, respectively. VEGF mRNA expression in relation to GAPDH mRNA was analyzed by densitometry.
Statistical analysis. All data are expressed as means ± SE. Statistical analysis was performed by one-way ANOVA followed by Student-Newman-Keul's multiple-comparison test or unpaired Student's t-test where appropriate. P < 0.05 was considered to be statistically significant.
| |
RESULTS |
|---|
|
|
|---|
Impaired myocardial capillary development in neonatal
eNOS
/
mice.
To determine the importance of eNOS in myocardial angiogenesis, we
first examined myocardial capillary vasculature in cross sections of
the left ventricular myocardium in neonatal mice. More abundant
capillary lumens were observed in the subepicardial region compared
with the middle layer or subendocardial region in both wild-type and
eNOS
/
mice. However, there were more well-developed
capillaries in wild-type mice (Fig.
1A) compared with
eNOS
/
mice (Fig. 1B). Immunostaining for vWF
also revealed an appreciable decrease in subepicardial regions of the
left ventricular wall in neonatal eNOS
/
mice (Fig.
1D) compared with wild-type mice (Fig. 1C).
Capillary densities in the subepicardial regions of the left
ventricular free wall were decreased by 40.7% in eNOS
/
neonates compared with neonatal wild-type mice (P < 0.01, n = 7 neonates/group; Fig.
2). However, in the adult left
ventricular myocardium, there was no significant difference in
capillary density (1,889 ± 157 vs. 2,027 ± 236 capillaries/mm2) between wild-type and
eNOS
/
mice [n = 4 mice/group,
P = not significant (NS)].
|
|
Impaired in vitro angiogenesis in eNOS
/
cardiac
endothelial cells.
Having documented the impairment of myocardial capillary development in
neonatal eNOS
/
mice, we conducted in vitro angiogenesis
of cardiac endothelial cells on Matrigel. Cardiac endothelial cells
isolated from five adult mice hearts were pooled onto one 6-well dish
as a primary culture. Five independent primary cultures were performed
in both wild-type and eNOS
/
mice. The cardiac
endothelial cells in the primary culture were allowed to grow to
complete confluence before they were seeded onto Matrigel-coated
96-well plates. Tube formation reached the optimal level after 4 h
of culture. The effects of NO on angiogenesis in cardiac endothelial
cells are shown by the representative images in Fig.
3. Compared with the wild type (Fig.
3A), tube formation was markedly decreased in
eNOS
/
cardiac endothelial cells (Fig. 3B).
Treatment with L-NAME decreased tube formation in wild-type
cardiac endothelial cells (Fig. 3C), whereas DETA-NO
increased tube formation in eNOS
/
cardiac endothelial
cells (Fig. 3D). Quantitative analysis showed that the total
length of tube between connections, the average thickness of tube, and
the number of capillary connections were significantly decreased in
eNOS
/
compared with wild-type cardiac endothelial cells
(Fig. 4, A-C; P < 0.05, n = 5 cells/group).
Treatment with L-NAME in wild-type cardiac endothelial
cells for 4 h caused a significant inhibition in total tube
length, average tube thickness, and number of connections by 27.9%,
25.1%, and 31.6%, respectively (Fig. 4; P < 0.05).
When DETA-NO was added to the medium for 4 h, the ability of
cardiac endothelial cells to form capillary-like structures was
significantly restored in eNOS
/
mice (Fig. 4;
P < 0.05).
|
|
Impaired in vivo myocardial angiogenesis in eNOS
/
mice.
The role of eNOS in angiogenesis was investigated in vivo by implanting
Matrigel in the left ventricular myocardium in anesthetized mice. Three
days after implantation, Matrigel was surrounded by fibrosis and was
easily identified in the myocardium. Massive in vivo angiogenesis was
observed with aneurysm-like structures in wild-type mice (Fig.
5A). However, there were only
small isolated vessels formed in Matrigel in eNOS
/
mice
(Fig. 5B). The area of capillaries and aneurysm-like
structures penetrating the Matrigel plug was quantified in relation to
the total Matrigel area. The percent vessel-like areas were
significantly decreased in eNOS
/
mice compared with
wild-type mice (Fig. 5C; n = 7 mice/group, P < 0.01).
|
Endogenous expression of VEGF in myocardium.
To determine whether impaired angiogenesis in eNOS
/
mice is associated with a reduction in endogenous VEGF expression, VEGF mRNA expression in the left ventricular myocardium was analyzed by
RT-PCR in both neonatal and adult mice. VEGF mRNA expression in
neonatal ventricular myocardium was significantly decreased in
eNOS
/
mice compared with wild-type mice
(n = 4 mice/group, P < 0.01; Fig.
6). However, VEGF mRNA expression in the
adult ventricular myocardium was similar between wild-type and
eNOS
/
mice (VEGF-to-GAPDH optical density ratio:
10.5 ± 0.4 vs. 9.4 ± 1.3, P = NS,
n = 3 mice/group).
|
| |
DISCUSSION |
|---|
|
|
|---|
The major finding of this study is that a deficiency in eNOS
resulted in significant impairment of myocardial capillary
development associated with decreased VEGF expression in the neonatal
mouse myocardium. Both in vitro and in vivo myocardial angiogenesis were significantly reduced in eNOS
/
mice. Furthermore,
in vitro tube formation was significantly inhibited by
L-NAME in wild-type mice, whereas decreased tube formation
in eNOS
/
mice was restored by DETA-NO. Taken together,
the present study indicates that a deficiency in eNOS decreases VEGF
expression and results in impairment of myocardial angiogenesis. NO
production from eNOS plays an important role in myocardial angiogenesis.
The morphology of endothelial cells and myocardial capillaries
gradually matures during late gestation, and by the early postnatal period there is dramatic growth of the coronary vascular bed
(25). In rats, the aggregate capillary length in the
ventricular myocardium doubles in the first 11 days postnatal,
suggesting that the postnatal period is critical for myocardial
capillary development (30). Interestingly, eNOS expression
is closely related to myocardial capillary development. Myocardial eNOS
expression is gradually increased during late gestation, and by birth
there is extensive eNOS expression in myocardial blood vessels and the
endocardium, a pattern that is similar to the adult heart
(32). In the present study, we demonstrated that
myocardial capillary densities were significantly decreased in neonatal
eNOS
/
mice, indicating an important role of eNOS in
myocardial capillary development. It is possible that decreased
myocardial capillary densities induce myocardial ischemia,
which may be responsible for the cardiac dysfunction and high mortality
in neonatal eNOS
/
mice (9).
A variety of models have been used for study of angiogenesis in vitro
and in vivo. In the present study, cardiac endothelial cells were used
for in vitro tube formation on Matrigel. We established for the first
time an intramyocardial Matrigel model in adult mice to assess in vivo
myocardial angiogenesis. The Matrigel could be implanted safely into
the mouse left ventricular wall. The unique benefit of this model
versus the subcutaneous Matrigel model is that angiogenesis in Matrigel
is formed by cardiac endothelial cells in myocardial milieu
(4). The Matrigel used in our assay is known to contain an
array of growth factors, including endothelial growth factors,
platelet-derived growth factor, insulin growth factor 1, transforming growth factor-
, etc. This permitted a direct analysis
of the requirement of eNOS in growth factor-stimulated angiogenesis.
NO has been identified as a downstream mediator of various growth
factors initiating the angiogenic signaling cascade in endothelial cells (2, 23), and eNOS is the predominant NOS isoform in VEGF-induced angiogenesis in vivo (11). In
ischemic limb and wound repair models, eNOS
/
mice showed significantly reduced angiogenesis (17, 20). Inhibition of eNOS by L-NAME attenuated endothelial cell
migration, one of the key events for angiogenesis (21).
The present study further extended the effects of NO on angiogenesis to
the heart. In vivo angiogenesis in Matrigel implanted in the left
ventricular myocardium was markedly decreased in eNOS
/
mice. In our in vitro angiogenesis assay, a primary culture of cardiac
endothelial cells was seeded on Matrigel to avoid possible loss of eNOS
after passages of the endothelial cells in wild-type mice
(1). In vitro tube formation from cardiac endothelial cells was significantly decreased in eNOS
/
mice. Total
tube length, average tube thickness, and the number of connections were
inhibited by L-NAME in wild-type mice and restored by
DETA-NO in eNOS
/
mice. The results demonstrated that
myocardial angiogenesis is NO dependent, and NO produced by eNOS plays
an important role in myocardial angiogenesis.
Studies have shown that VEGF mRNA is strongly expressed in the
myocardium, and coronary capillary growth is dependent on VEGF during
the prenatal and early postnatal period (30, 31).
Deficiency of VEGF164 and VEGF188 impairs
myocardial angiogenesis and induces ischemic cardiomyopathy
(5). Partial VEGF inhibition achieved by inducible gene
targeting leads to impaired organ development and increased mortality
in mice (12). Increased NO production from eNOS induces
VEGF expression in vascular smooth muscle cells (7).
However, it is not known whether a deficiency of eNOS alters VEGF
expression in neonatal hearts. In the present study, we demonstrated
that VEGF expression was significantly decreased in neonatal
eNOS
/
mice, which was consistent with a decrease in
capillary densities. The result suggests that lack of eNOS decreases
VEGF expression and may contribute to impaired myocardial capillary
development in neonatal eNOS
/
mice.
The potential mechanism underlying the attenuation of VEGF expression
in the neonatal eNOS
/
heart is not completely
understood. It has been shown that there is a positive feedback between
NO and VEGF. NO is not only a downstream mediator of VEGF-induced
endothelial cell proliferation and migration but also an upstream
promoter of VEGF expression (15). It has been demonstrated
that NO increases the transcriptional activity of the VEGF promotor in
vascular smooth muscle cells (15) and skeletal muscle
(3). In addition, NO prolonged the half-life of VEGF mRNA
(6). It is possible that lack of NO production in
eNOS
/
mice abrogates the positive feedback mechanism
between NO and VEGF and causes a decrease in VEGF expression.
In adult eNOS
/
mice, however, capillary densities were
not altered. Our results are consistent with a recent report
(16) that demonstrated similar myocardial capillary
densities in cardiac and skeletal muscles between adult
eNOS
/
and wild-type mice. We did not detect any
significant changes of VEGF expression in the myocardium of adult
eNOS
/
mice either. These data agree with a previous
report (20) that showed that VEGF expression in skeletal
muscle was not altered in adult eNOS
/
mice compared
with wild-type mice (20). The mechanism related to
well-developed capillary densities in adult eNOS
/
mice
is not clear. It is possible that proangiogenic factors are upregulated
and compensated for the loss of eNOS function and promote postnatal
development of myocardial capillaries in those surviving
eNOS
/
mice. Lack of eNOS may induce postnatally an
increase in some angiogenic factors, such as angiotensin
(22) and prostaglandins (13). Whether these
factors are involved in the myocardial capillary development in adult
eNOS
/
mice requires further investigation.
In summary, neonatal mice deficient in eNOS showed decreased VEGF
expression and impaired capillary development in the myocardium. Both
in vitro and in vivo myocardial angiogenesis were decreased in
eNOS
/
mice. Our results demonstrated an important role
of eNOS in myocardial capillary development and angiogenesis. Decreased
myocardial angiogenesis may represent an important mechanism in the
myocardial apoptosis, heart failure, and high mortality we
recently observed in neonatal eNOS
/
mice
(9).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Keith D. Hutcheson for technical assistance in histological preparations.
| |
FOOTNOTES |
|---|
This study was supported by Canadian Institutes of Health Research (CIHR) Grant MT-14653 and Heart and Stroke Foundation of Ontario Grant T4045 (to Q. Feng). Q. Feng was supported by a Research Career Award from the Rx&D Health Research Foundation and CIHR. X. Zhao was a postdoctoral fellow from Department of Cardiology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Address for reprint requests and other correspondence: Q. Feng, Dept. of Medicine, London Health Sciences Centre, Victoria Campus, 375 South St., London, Ontario, Canada N6A 4G5 (E-mail: qfeng{at}uwo.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
August 22, 2002;10.1152/ajpheart.00383.2002
Received 1 May 2002; accepted in final form 13 August 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Ando, H,
Kubin T,
Schaper W,
and
Schaper J.
Cardiac microvascular endothelial cells express
-smooth muscle actin and show low NOS III activity.
Am J Physiol Heart Circ Physiol
276:
H1755-H1768,
1999
2.
Babaei, S,
Teichert-Kuliszewska K,
Monge JC,
Mohamed F,
Bendeck MP,
and
Stewart DJ.
Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor.
Circ Res
82:
1007-1015,
1998
3.
Benoit, H,
Jordan M,
Wagner H,
and
Wagner PD.
Effect of NO, vasodilator prostaglandins, and adenosine on skeletal muscle angiogenic growth factor gene expression.
J Appl Physiol
86:
1513-1518,
1999
4.
Bussolati, B,
Dunk C,
Grohman M,
Kontos CD,
Mason J,
and
Ahmed A.
Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
Am J Pathol
159:
993-1008,
2001
5.
Carmeliet, P,
Ng YS,
Nuyens D,
Theilmeier G,
Brusselmans K,
Cornelissen I,
Ehler E,
Kakkar VV,
Stalmans I,
Mattot V,
Perriard JC,
Dewerchin M,
Flameng W,
Nagy A,
Lupu F,
Moons L,
Collen D,
D'Amore PA,
and
Shima DT.
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.
Nat Med
5:
495-502,
1999[ISI][Medline].
6.
Chin, K,
Kurashima Y,
Ogura T,
Tajiri H,
Yoshida S,
and
Esumi H.
Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells.
Oncogene
15:
437-442,
1997[ISI][Medline].
7.
Dulak, J,
Jozkowicz A,
Dembinska-Kiec A,
Guevara I,
Zdzienicka A,
Zmudzinska-Grochot D,
Florek I,
Wojtowicz A,
Szuba A,
and
Cooke JP.
Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol
20:
659-666,
2000
8.
Feng, Q,
Lu X,
Jones DL,
Shen J,
and
Arnold JMO
Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice.
Circulation
104:
700-704,
2001
9.
Feng, Q,
Song W,
Lu X,
Hamilton JA,
Lei M,
Peng T,
and
Yee SP.
Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase.
Circulation
106:
873-879,
2002
10.
Ferrara, N,
and
Davis-Smyth T.
The biology of vascular endothelial growth factor.
Endocr Rev
18:
4-25,
1997
11.
Fukumura, D,
Gohongi T,
Kadambi A,
Izumi Y,
Ang J,
Yun CO,
Buerk DG,
Huang PL,
and
Jain RK.
Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability.
Proc Natl Acad Sci USA
98:
2604-2609,
2001
12.
Gerber, HP,
Hillan KJ,
Ryan AM,
Kowalski J,
Keller GA,
Rangell L,
Wright BD,
Radtke F,
Aguet M,
and
Ferrara N.
VEGF is required for growth and survival in neonatal mice.
Development
126:
1149-1159,
1999[Abstract].
13.
Godecke, A,
Decking UK,
Ding Z,
Hirchenhain J,
Bidmon HJ,
Godecke S,
and
Schrader J.
Coronary hemodynamics in endothelial NO synthase knockout mice.
Circ Res
82:
186-194,
1998
14.
Hefler, LA,
Reyes CA,
O'Brien WE,
and
Gregg AR.
Perinatal development of endothelial nitric oxide synthase-deficient mice.
Biol Reprod
64:
666-673,
2001
15.
Jozkowicz, A,
Cooke JP,
Guevara I,
Huk I,
Funovics P,
Pachinger O,
Weidinger F,
and
Dulak J.
Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF.
Cardiovasc Res
51:
773-783,
2001
16.
Kubis, N,
Besnard S,
Silvestre JS,
Feletou M,
Huang PL,
Levy BI,
and
Tedgui A.
Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme.
J Hypertens
20:
273-280,
2002[ISI][Medline].
17.
Lee, PC,
Salyapongse AN,
Bragdon GA,
Shears LL, 2nd,
Watkins SC,
Edington HD,
and
Billiar TR.
Impaired wound healing and angiogenesis in eNOS-deficient mice.
Am J Physiol Heart Circ Physiol
277:
H1600-H1608,
1999
18.
Lee, TC,
Zhao YD,
Courtman DW,
and
Stewart DJ.
Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase.
Circulation
101:
2345-2348,
2000
19.
Matsunaga, T,
Warltier DC,
Weihrauch DW,
Moniz M,
Tessmer J,
and
Chilian WM.
Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide.
Circulation
102:
3098-3103,
2000
20.
Murohara, T,
Asahara T,
Silver M,
Bauters C,
Masuda H,
Kalka C,
Kearney M,
Chen D,
Symes JF,
Fishman MC,
Huang PL,
and
Isner JM.
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.
J Clin Invest
101:
2567-2578,
1998[ISI][Medline].
21.
Murohara, T,
Witzenbichler B,
Spyridopoulos I,
Asahara T,
Ding B,
Sullivan A,
Losordo DW,
and
Isner JM.
Role of endothelial nitric oxide synthase in endothelial cell migration.
Arterioscler Thromb Vasc Biol
19:
1156-1161,
1999
22.
Otani, A,
Takagi H,
Suzuma K,
and
Honda Y.
Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells.
Circ Res
82:
619-628,
1998
23.
Papapetropoulos, A,
Garcia-Cardena G,
Madri JA,
and
Sessa WC.
Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.
J Clin Invest
100:
3131-3139,
1997[ISI][Medline].
24.
Passaniti, A,
Taylor RM,
Pili R,
Guo Y,
Long PV,
Haney JA,
Pauly RR,
Grant DS,
and
Martin GR.
A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.
Lab Invest
67:
519-528,
1992[ISI][Medline].
25.
Porter, GA,
and
Bankston PW.
Myocardial capillaries in the fetal and the neonatal rat: a morphometric analysis of the maturing myocardial capillary bed.
Am J Anat
179:
108-115,
1987[ISI][Medline].
26.
Risau, W.
Mechanisms of angiogenesis.
Nature
386:
671-674,
1997[Medline].
27.
Rui, T,
Cepinskas G,
Feng Q,
Ho YS,
and
Kvietys PR.
Cardiac myocytes exposed to anoxia-reoxygenation promote neutrophil transendothelial migration.
Am J Physiol Heart Circ Physiol
281:
H440-H447,
2001
28.
Tabibiazar, R,
and
Rockson SG.
Angiogenesis and the ischaemic heart.
Eur Heart J
22:
903-819,
2001
29.
Tomanek, RJ,
Lotun K,
Clark EB,
Suvarna PR,
and
Hu N.
VEGF and bFGF stimulate myocardial vascularization in embryonic chick.
Am J Physiol Heart Circ Physiol
274:
H1620-H1626,
1998
30.
Tomanek, RJ,
Sandra A,
Zheng W,
Brock T,
Bjercke RJ,
and
Holifield JS.
Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis.
Circ Res
88:
1135-1141,
2001
31.
Tomanek, RJ,
Zheng W,
Peters KG,
Lin P,
Holifield JS,
and
Suvarna PR.
Multiple growth factors regulate coronary embryonic vasculogenesis.
Dev Dyn
221:
265-273,
2001[ISI][Medline].
32.
Ursell, PC,
and
Mayes M.
Endothelial isoform of nitric oxide synthase in rat heart increases during development.
Anat Rec
246:
465-472,
1996[Medline].
This article has been cited by other articles:
![]() |
A. Makino, O. Platoshyn, J. Suarez, J. X.-J. Yuan, and W. H. Dillmann Downregulation of connexin40 is associated with coronary endothelial cell dysfunction in streptozotocin-induced diabetic mice Am J Physiol Cell Physiol, July 1, 2008; 295(1): C221 - C230. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Viita, J. Markkanen, E. Eriksson, M. Nurminen, K. Kinnunen, M. Babu, T. Heikura, S. Turpeinen, S. Laidinen, T. Takalo, et al. 15-Lipoxygenase-1 Prevents Vascular Endothelial Growth Factor A- and Placental Growth Factor-Induced Angiogenic Effects in Rabbit Skeletal Muscles via Reduction in Growth Factor mRNA Levels, NO Bioactivity, and Downregulation of VEGF Receptor 2 Expression Circ. Res., February 1, 2008; 102(2): 177 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Genis, P. Gonzalo, A. S. Tutor, B. G. Galvez, A. Martinez-Ruiz, C. Zaragoza, S. Lamas, K. Tryggvason, S. S. Apte, and A. G. Arroyo Functional interplay between endothelial nitric oxide synthase and membrane type 1 matrix metalloproteinase in migrating endothelial cells Blood, October 15, 2007; 110(8): 2916 - 2923. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Hammoud, F. Xiang, X. Lu, F. Brunner, K. Leco, and Q. Feng Endothelial nitric oxide synthase promotes neonatal cardiomyocyte proliferation by inhibiting tissue inhibitor of metalloproteinase-3 expression Cardiovasc Res, July 15, 2007; 75(2): 359 - 368. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Suzuki Microvascular angioadaptation after endurance training with L-arginine supplementation in rat heart and hindleg muscles Exp Physiol, September 1, 2005; 90(5): 763 - 771. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Milkiewicz, O. Hudlicka, M. D. Brown, and H. Silgram Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H336 - H343. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Janssens, P. Pokreisz, L. Schoonjans, M. Pellens, P. Vermeersch, M. Tjwa, P. Jans, M. Scherrer-Crosbie, M. H. Picard, Z. Szelid, et al. Cardiomyocyte-Specific Overexpression of Nitric Oxide Synthase 3 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction Circ. Res., May 14, 2004; 94(9): 1256 - 1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ni, P. Moulin, P. Gianello, O. Feron, J.-L. Balligand, and O. Devuyst Mice that Lack Endothelial Nitric Oxide Synthase Are Protected against Functional and Structural Modifications Induced by Acute Peritonitis J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3205 - 3216. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ou, Z. Ou, D. G. McCarver, R. N. Hines, K. T. Oldham, A. W. Ackerman, and K. A. Pritchard Jr. Trichloroethylene Decreases Heat Shock Protein 90 Interactions with Endothelial Nitric Oxide Synthase: Implications for Endothelial Cell Proliferation Toxicol. Sci., May 1, 2003; 73(1): 90 - 97. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |